SAWAI GROUP HOLDINGS Co., Ltd. (JP:4887)
:4887
Top Page
SAWAI GROUP HOLDINGS Co., Ltd.
(4887)
Select Model
Select Model
Rating:59Neutral
Price Target:
¥2,223.00
▼(-5.77% Downside)
Action:ReiteratedDate:02/18/26
The score is held back primarily by inconsistent free-cash-flow generation and recent margin compression despite strong TTM revenue growth, alongside a negative P/E that reduces valuation clarity. Technicals are mixed, with weaker short-term trend but support from longer-term moving averages, and the dividend yield is moderate.
Positive Factors
Strong Revenue Growth
A sustained 34% TTM top-line increase indicates durable demand for the company’s generics portfolio and expanding sales scale in its core domestic market. Strong revenue momentum supports reinvestment capacity and provides a base to offset pricing or cost pressures over 2–6 months.
Negative Factors
Margin Compression
Net margin decline from ~12.1% to ~4.9% TTM signals structural pressure on profitability, likely from pricing, mix shifts or cost increases. Persistently lower margins will reduce internal funding for growth and weaken returns, making long-term margin recovery a key risk.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Revenue Growth
A sustained 34% TTM top-line increase indicates durable demand for the company’s generics portfolio and expanding sales scale in its core domestic market. Strong revenue momentum supports reinvestment capacity and provides a base to offset pricing or cost pressures over 2–6 months.
Read all positive factors
SAWAI GROUP HOLDINGS Co., Ltd. (4887) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥224.36B
Dividend Yield2.28%
Average Volume (3M)299.27K
Price to Earnings (P/E)13.9
Beta (1Y)0.38
Revenue Growth12.78%
EPS Growth-105.43%
CountryJP
Employees3,482
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)42.46
Shares Outstanding115,487,140
10 Day Avg. Volume288,420
30 Day Avg. Volume299,266
Financial Highlights & Ratios
PEG Ratio-0.24
Price to Book (P/B)1.41
Price to Sales (P/S)1.30
P/FCF Ratio33.73
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥2,640.00Price Target Upside11.91% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)172.91
Revenue Forecast (FY)¥218.18B
SAWAI GROUP HOLDINGS Co., Ltd. Business Overview & Revenue Model
Company Description
Sawai Group Holdings Co., Ltd., together with subsidiaries, engages in the research, development, manufacturing, and marketing of generic pharmaceutical products primarily in Japan and the United States. It offers generic drugs in various dosage f...
How the Company Makes Money
The company makes money mainly through the sale of pharmaceutical products manufactured and marketed by its operating subsidiaries. Its primary revenue stream is domestic (Japan) sales of generic prescription medicines supplied to medical institut...
SAWAI GROUP HOLDINGS Co., Ltd. Financial Statement Overview
Summary
Income Statement
74
Positive
Balance Sheet
70
Positive
Cash Flow
58
Neutral
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 200.68B | 189.02B | 176.86B | 200.34B | 193.82B | 187.22B |
| Gross Profit | 57.97B | 56.35B | 54.32B | 62.63B | 68.95B | 72.43B |
| EBITDA | 14.32B | 19.44B | 36.88B | 34.87B | -20.18B | 35.75B |
| Net Income | -2.74B | 11.97B | 13.70B | 12.67B | -28.27B | 12.34B |
Balance Sheet | ||||||
| Total Assets | 377.03B | 354.62B | 382.02B | 364.17B | 349.50B | 393.34B |
| Cash, Cash Equivalents and Short-Term Investments | 46.12B | 38.78B | 26.37B | 33.08B | 47.72B | 54.27B |
| Total Debt | 122.49B | 95.11B | 87.13B | 77.07B | 70.80B | 70.58B |
| Total Liabilities | 198.23B | 180.77B | 163.99B | 151.43B | 149.42B | 152.59B |
| Stockholders Equity | 178.80B | 173.85B | 212.66B | 201.64B | 190.07B | 218.28B |
Cash Flow | ||||||
| Free Cash Flow | 5.85B | 7.28B | 5.23B | -7.70B | 19.80B | 18.86B |
| Operating Cash Flow | 20.29B | 27.85B | 23.15B | 13.03B | 34.31B | 31.86B |
| Investing Cash Flow | -24.94B | 6.48B | -23.11B | -27.13B | -30.39B | -21.79B |
| Financing Cash Flow | 14.93B | -32.70B | 2.36B | -1.27B | -11.26B | -11.99B |
SAWAI GROUP HOLDINGS Co., Ltd. Technical Analysis
Positive
2359.00
Price Trends
2254.99
Positive
2219.79
Positive
2051.83
Positive
Market Momentum
12.23
Negative
52.20
Neutral
42.50
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4887, the sentiment is Positive. The current price of 2359 is above the 20-day moving average (MA) of 2213.42, above the 50-day MA of 2254.99, and above the 200-day MA of 2051.83, indicating a bullish trend. The MACD of 12.23 indicates Negative momentum. The RSI at 52.20 is Neutral, neither overbought nor oversold. The STOCH value of 42.50 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4887.
SAWAI GROUP HOLDINGS Co., Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | ¥191.98B | 14.92 | 6.70% | 2.48% | 13.11% | 41.57% | |
77 Outperform | ¥347.00B | 9.44 | ― | 2.12% | 4.07% | 22.59% | |
76 Outperform | ¥72.76B | 8.62 | ― | 2.52% | 5.44% | -20.33% | |
68 Neutral | ¥63.21B | 35.63 | 5.01% | 2.39% | 12.01% | -51.38% | |
67 Neutral | ¥209.41B | 5.05 | 12.02% | 2.14% | 9.32% | 30.85% | |
59 Neutral | ¥224.36B | 13.89 | ― | 2.28% | 12.78% | -105.43% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
JP:4887
SAWAI GROUP HOLDINGS Co., Ltd.
2,255.50
407.87
22.08%
JP:4547
Kissei Pharmaceutical Co
4,700.00
1,189.32
33.88%
JP:4553
Towa Pharmaceutical Co
4,255.00
1,871.39
78.51%
JP:4554
Fuji Pharma Co., Ltd.
2,464.00
1,201.57
95.18%
JP:4516
Nippon Shinyaku Co., Ltd.
5,152.00
1,744.49
51.20%
JP:4886
ASKA Pharmaceutical Holdings Co., Ltd.
2,734.00
489.04
21.78%
SAWAI GROUP HOLDINGS Co., Ltd. Corporate Events
Sawai Group Posts Profit Drop on Higher Sales, Keeps Dividend and Sees Earnings Rebound
Feb 13, 2026
Sawai Group Holdings reported consolidated revenue of ¥154.9 billion for the nine months ended Dec. 31, 2025, up 8.1% year-on-year, but operating profit fell 25.7% to ¥15.9 billion and profit attributable to owners of the parent slumped ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.